4506 logo

Sumitomo Pharma Co., Ltd. Stock Price

TSE:4506 Community·JP¥905.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

4506 Share Price Performance

JP¥2,279.00
1701.00 (294.29%)
JP¥1,520.00
Fair Value
JP¥2,279.00
1701.00 (294.29%)
49.9% overvalued intrinsic discount
JP¥1,520.00
Fair Value
Price JP¥2,279.00
AnalystLowTarget JP¥1,520.00

4506 Community Narratives

AnalystLowTarget·
Fair Value JP¥1.52k 49.9% overvalued intrinsic discount

Pipeline Risks And Margin Compression Will Drive Long-Term Earnings Declines

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
JP¥1.52k
49.9% overvalued intrinsic discount
Revenue
2.54% p.a.
Profit Margin
6.59%
Future PE
21.98x
Price in 2028
JP¥1.75k

Trending Discussion

Updated Narratives

4506 logo

Pipeline Risks And Margin Compression Will Drive Long-Term Earnings Declines

Fair Value: JP¥1.52k 49.9% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with slight risk.

4 Risks
4 Rewards

Sumitomo Pharma Co., Ltd. Key Details

JP¥445.2b

Revenue

JP¥170.8b

Cost of Revenue

JP¥274.4b

Gross Profit

JP¥119.7b

Other Expenses

JP¥154.7b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Jan 30, 2026
389.45
61.63%
34.75%
99.0%
View Full Analysis

About 4506

Founded
1897
Employees
3832
CEO
Toru Kimura
WebsiteView website
www.sumitomo-pharma.com

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Recent 4506 News & Updates

Recent updates

No updates